African Pioneer Share Discussion Threads

[currypasty] 05/12/2006 14:46

perhaps morgan stanley have bought more ?

[currypasty] 05/12/2006 14:44

I bought mine for the EIS tax breaks, and i think they have just a year to run, so im staying put, and hoping the good work continues!

the 2*500k put/shut could something to do with this rise, its unusually large for this share

[tiltonboy] 05/12/2006 14:40

£4m profit would put the shares on a p/e of 15, using a 25% tax charge.

[ltinvestor] 05/12/2006 14:34

I think that the figure could be between £3.5m-£4m!! but we should have a better idea when the interims are announced.If I am correct then very low p/e.

[tiltonboy] 05/12/2006 14:31

CURRY,

Any thoughts on EPS for the current year?

With a historic p/e of 25, it's tempting to take profits, but if the prospective is 15, then they could run a bit further.

tiltonboy

[currypasty] 05/12/2006 14:29

take off 41.0 - 43.0

[currypasty] 05/12/2006 14:19

40p all time high !

[currypasty] 04/12/2006 10:29

back to the 39p level, will it push through this time ?

[currypasty] 21/11/2006 13:47

RNS Number:4288M
Ascribe plc
21 November 2006


Ascribe plc (the "Company")

Holding in Company


The Company was informed on 20 November 2006 by Morgan Stanley Securities
Limited ("MSSL") that on 17 November 2006 MSSL acquired an interest that
resulted in a total holding of 5,051,599 ordinary shares of 1p each in the
Company, representing 4.42 per cent. of the Company's current issued ordinary
share capital.

[currypasty] 30/10/2006 15:48

house broker must be moving these shares on ?



Holding(s) in Company

RNS Number:2338L
Ascribe plc
30 October 2006




Ascribe plc (the "Company")

Holding in Company


The Company was informed on 20 October 2006 by Morgan Stanley Securities Limited
("MSSL") that MSSL was interested in 5,013,216 ordinary shares of 1p each in the
Company ("Ordinary Shares"), representing 4.39 per cent. of the Company's
current issued ordinary share capital, and on 23 October 2006 by MSSL that MSSL
was interested in 4,551,599 Ordinary Shares, representing 3.98 per cent. of the
Company's current issued ordinary share capital.

[tiltonboy] 17/10/2006 15:14

The house brokers still sitting on the offer!!!

[tiltonboy] 21/9/2006 15:47

CURRY,

That is the same number of shares they previously held, but after the issue of new shares by ASP, their % holding has fallen below 11%.

tiltonboy

[currypasty] 21/9/2006 15:03

RNS Number:2968J
Ascribe plc
21 September 2006


Ascribe plc (the "Company")

Holding in Company


The Company was informed on 19 September 2006 by Artemis Investment Management
Limited ("Artemis") that Artemis and certain of its investment clients are
interested in 12,212,497 ordinary shares of 1p each in the Company ("Ordinary
Shares"), representing 10.70 per cent. of the Company's current issued ordinary
share capital.

[piedro] 19/9/2006 14:33

New COO
Last week bought his first batch of 300,000 shares
Only been a Director since Febuary.
Was Operations Director with Independent British Health then moved to Hong Kong !!!

AND,
......" a director of Hybrid-4 Ltd which was placed into voluntary
administration on 2 August 2006".

Something fishy ?
Am I being paranoic ?
Anyone know what happened at Hybrid-4 ?

[ltinvestor] 18/9/2006 13:25

Expect £3.5m plus for 2007.

[tiltonboy] 18/9/2006 10:17

CURRY,

What do you think the right price for these is?

I'm attracted by the high level of maintenance revenue(62%), and high EPS growth.

I do not normally like companies on p'e's of above 20, but these still look good value.

Are there any numbers out there for 2007?

tiltonboy

[currypasty] 18/9/2006 10:04

31k buy at a penny over ask


cnks still holding the price

[currypasty] 18/9/2006 08:55

yes, it was sent over the weekend via the free tip sheet uk-analyst

[matrix74] 18/9/2006 08:26

Hi Curry pasty, I thought that Ascribe was tipped a week or so ago? Was it re released somewhere today?
Thanks

[currypasty] 18/9/2006 07:43

Buy Ascribe at 36p

A tip from Techinvest Newsletter
Back in 2001, The Audit Commission published a report entitled "A Spoonful of Sugar". In this it said there was potentially up to 1,200 lives and 500 million pounds a year that could be saved by UK hospitals if they used clinical information systems to reduce patient medication errors. Similar such reports in the US showed that the problem certainly wasn't localised in the UK . In 2004, another study issued by Liverpool University said that UK citizens were more likely to die from a "medical misadventure" than from a road traffic accident. Fairly sobering reading which the Government took to heart. It has since issued hospitals with targets to reduce the number of medication errors that occur.

As a result, demand for clinical management systems has boomed. This is an area that Ascribe has focused on since it was established back 1984 (then called ASC Computer Software) by Chairman and Pharmacist Stephen Critchlow and Dr Chris Jones. They originally developed software to overcome the difficulties they were having handling clinical information while working for the NHS.

The Company was floated on AIM in December 2004 in order to raise funds to acquire Protechnic Exeter, a health IT Company which supplied primary care trusts and GPs with community and child health systems. Since then, Ascribe has gone from strength to strength, which hasn't been adequately reflected in the share price - 32p compared with an IPO price of 18p. Recent weakness in the stock market has given subscribers a chance to get on board.

*This email represents the views of UK-Analyst and are not the views of IG Index. Remember that spread betting is a leveraged product and can result in losses that exceed your initial deposit. It may not be suitable for everyone, so please ensure that you fully understand the risks involved. The value of investments can go down as well as up. Investing in equities can lose you part or all of your capital. Smaller company shares can be relatively illiquid and thus hard to trade. And that makes such investments more of a high risk than larger company shares. UK-Analyst.com is owned by t1ps.com which is authorised and regulated by the FSA and can be contacted at 49 Rivington St, London EC2A 3QB or on 0207 033 9389.

A January 2002 Silicon Bridge Research report estimated that over 40% of the UK Secondary Care market used an Ascribe system, making it the then largest supplier of pharmacy software. Since then, Ascribe has won over 90% of the public tenders it has competed for in the UK . It has also sold systems in Australia , New Zealand , Malaysia and Hong Kong . Originally there were four main Ascribe products, which could be used alone or in combination to provide an appropriate medicines management solution: Pharmacy, used to assist hospital pharmacies to dispense medicine and includes stock control, labelling, drug level monitoring and drug utilisation reporting; Electronic Prescribing, used by doctors to send prescriptions directly to dispensing pharmacies; Clinical Decision Support, used by medical staff to check prescriptions with reference to the condition of a particular patient; Integrated Clinical Workstation, a system capable of integrating legacy systems to offer clinicians a single clinical view, a solution suggested in The Audit Commission report.




Ascribe floated on AIM to finance its first acquisition, but it certainly hasn't stopped there. In the intervening period it has completed a further six, taking it into complementary areas while at the same time enhancing earnings. In May 2005 it moved into A&E when it acquired Footman Walker, a leading supplier of A&E information systems in the UK with a 30% market share. A month later, Ascribe took over Park Systems, the largest independent supplier of retail pharmacy computer systems in the UK . At the same time it bought Archive, a supplier of software to Protechnic Exeter. Barwick Systems was added in March this year. It supplies Patient Administration Systems (PAS) to NHS hospitals. Many also use Ascribe's Pharmacy or A&E systems.

In May, Ascribe broadened its geographic reach acquiring the health division of private New Zealand-company Jade Software. This gave it greater expertise in mental health and more Australasian sales: Jade provides IT solutions to 24 hospitals and health organisations. A month later Ascribe acquired HE Information Systems (HEIS), another supplier of PAS to 21 NHS hospitals for up to 6.5 million pounds. As with Barwick Systems, many of HEIS's clients also use Ascribe's Pharmacy or A&E systems. In the year ended 31 March 2005 , HEIS made a pre-tax profit of 0.52 million pounds from turnover of 2.5 million pounds and will enhance earnings in its first year of ownership.

A record result was achieved for the year ended June 30 as sales surged 85% to 9.9 million pounds. The three recent acquisitions contributed 0.93 million pounds. Recurring maintenance revenue accounted for 62% of sales. Profit before tax and goodwill amortisation was 2 million pounds, compared with 0.8 million pounds last time. This gave earnings per share of 1.59p (0.64p). Cash inflow from operations was 2.4 million pounds, which easily covering reported operating profit. Net debt after the acquisitions was 0.52 million pounds. With sales underpinned by the high proportion of recurring revenue, Ascribe is a high growth stock with little downside risk. Two directors gave a vote of confidence in June when they added to their holdings. Follow their lead. Buy.

Techinvest is the one of the few investment newsletters with years of experience in successfully helping investors make money from the tech sector of the London Stockmarket.

[currypasty] 12/9/2006 07:56

RNS Number:8016I
Ascribe plc
12 September 2006

Press Release 12 September 2006



Ascribe plc

("Ascribe" or "the Group")

Preliminary Results

Bolton, UK: Ascribe (AIM:ASP), the health IT Group, today announces its
Preliminary Results for the year ended 30 June 2006.

Highlights


- Revenues up 85% to #9.9m (2005: #5.3m)
- Successful completion and integration of three significant acquisitions
- Like for like revenues up 15%
- Recurring maintenance revenue at 62% (2005: 61%)
- Earnings before interest, taxation, depreciation and amortisation(1)
(EBITDA) increased 111% to #2.3m (2005: #1.1m)
- Adjusted operating profit(2) up 141% to #2.2m (2005: #0.9m)
- Operating margin(2) of 22% (2005: 17%)
- Adjusted profit before tax(2) up 129% to #2.2m
- Profit before tax up by 111% to #1.4m (2005: #0.7m)
- Operating cash is 112% of operating profit
- Adjusted earnings per share(2) up 86% to 1.73p (2005: 0.93p)
- Dividend of 0.13p per share proposed - an increase of 30% on last year

[currypasty] 11/9/2006 08:46

there is a string of 10k buys this morning... i wonder if thats the online dealing limit

2 mm bid 36.0
1 mm ask 37.0